Chinese inactivated COVID-19 vaccine starts phase-3 clinical trials in Argentina

A staff member displays a sample of the COVID-19 inactivated vaccine at a vaccine production plant of China National Pharmaceutical Group Co., Ltd. (Sinopharm) in Beijing, capital of China, April 10, 2020. (Xinhua/Zhang Yuwei)

BEIJING, Aug. 22 (Xinhua) -- An inactivated COVID-19 vaccine developed by China has started phase-3 clinical trials in Argentina, according to its developer China National Biotec Group (CNBG), which is affiliated to Sinopharm.

The launch ceremony of the phase-3 clinical trials was held in Beijing Friday after the CNBG obtained the certificate of approval for the process.

This is an achievement brought about by CNBG's international cooperation in a bid to develop a COVID-19 vaccine. The inactivated vaccine received approval for phase-3 clinical trials in the United Arab Emirates on June 23, and in Peru and Morocco on Thursday.

The CNBG will work together with a company in Argentina to promote research and development related to the inactivated vaccine.

Liu Jingzhen, chairman of Sinopharm, said the phase-3 clinical trials will help fight the epidemic and contribute to the building of a community of health for all.